To print: Select File and then Print from your browser's menu

Title: Escitalopram Helps Prevent Relapse of Obsessive-Compulsive Disorder Symptoms: Presented at APA

"Escitalopram Helps Prevent Relapse of Obsessive-Compulsive Disorder Symptoms: Presented at APA"

By Danny Kucharsky TORONTO, CANADA -- May 25, 2006 -- Escitalopram 10 mg/day or 20 mg/day significantly reduces the risk of relapse in patients with obsessive-compulsive disorder (OCD), according to a study presented here at the American Psychiatric Association Annual Meeting (APA). The study found escitalopram at both doses had an anti-OCD effect during 16 weeks of open-label treatment and a significant relapse-preventing effect during continued treatment up to 24 weeks, said investigator Naomi Fineberg, MD, professor of psychiatry, Postgraduate Medical School, University of Hertfordshire, Hatfield, United Kingdom. The study was a multinational, randomized, double-blind, placebo-controlled, flexible to fixed dose relapse prevention study in 2 phases: a 16-week, open-label period followed by a 24-week, double-blind, placebo-controlled period and a 1-week taper period. Patients who responded to treatment by the end of the 16 week open-label period were eligible for randomization. Of the 468 patients entering the open-label period, 94 withdrew, and of the remaining 374, 320 were randomized to double-blind treatment -- 163 to escitalopram and 157 to placebo. Patients withdrew if they relapsed or if the patient or doctor decided to discontinue treatment. "With an open-label phase you are going to get more people who withdraw," Dr. Fineberg said in her presentation on May 23[^rd.

Twenty-eight of the withdrawals were for adverse events, most of which were mild to moderate. One patient was withdrawn due to suicidal thoughts.

During the 24-week, double-blind period, the overall withdrawal rate, excluding relapses, was comparable for both treatments: 7.9% for escitalopram-treated patients (n = 13) and 8.9% for placebo-treated patients (n = 14). Escitalopram "was reasonably well tolerated and most patients did well," Dr. Fineberg said.

Time to relapse of OCD over 24 weeks showed a significant advantage for patients treated with escitalopram compared with patients treated with placebo (P <.001; log-rank test). The proportion of patients who relapsed was significantly higher in the placebo group than in the escitalopram group (52% vs 24%, P <.001).

The risk of relapse was 2.74 times higher for placebo-treated patients than for escitalopram-treated patients. Both the 10-mg and 20-mg escitalopram subgroups were significantly superior to the corresponding placebo subgroups in the analysis of time to relapse.

The study was sponsored by H. Lundbeck A/S.

[Presentation title: Escitalopram in Relapse Prevention in Patients With Obsessive-Compulsive Disorder (OCD). Abstract NR504]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.